LEO Pharma

Timber Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for orphan dermatologic diseases. The company specializes in creating non-systemic therapies aimed at addressing rare skin conditions, such as congenital ichthyosis and various sclerotic skin diseases. Its investigational drugs are supported by extensive clinical experience, showcasing established safety profiles and manufacturing processes. Among its key products, TMB-001 represents a late-stage program, while TMB-003 is in the earlier stages of development. Timber Pharmaceuticals focuses on delivering innovative solutions for patients affected by these rare dermatologic disorders.

SkinVision is an awareness and tracking solution that supports individuals with the early recognition of melanoma, squamous cell carcinoma, basal cell carcinoma and precancerous actinic keratosis. SkinVision is the first certified skin cancer application globally based on extensive clinical trials in partnership with the university clinic of Ludwig Maximilian University (LMU) in Munich in 2013, published in the JEADV in 2014. The company has built up a customer portfolio of 1,200,000 users globally and a database of 3,5 million pictures of suspicious skin conditions.

NØIE is a skincare company that offers personalized skincare products and solutions for dry skin, acne, eczema, psoriasis, and more. An algorithm is used in the company's skin test to assign customers to their skin family and recommend customized products to suit their skin. Additionally, CO2-neutral deliveries are provided, compensating for carbon emissions generated during the shipping process by planting trees in Denmark. The company aims to improve the quality of life for each individual with skin issues. NØIE was founded in 2019 and is headquartered in Copenhagen, Denmark.

SkinVision is an awareness and tracking solution that supports individuals with the early recognition of melanoma, squamous cell carcinoma, basal cell carcinoma and precancerous actinic keratosis. SkinVision is the first certified skin cancer application globally based on extensive clinical trials in partnership with the university clinic of Ludwig Maximilian University (LMU) in Munich in 2013, published in the JEADV in 2014. The company has built up a customer portfolio of 1,200,000 users globally and a database of 3,5 million pictures of suspicious skin conditions.

Peplin is a development-stage specialty pharmaceutical company that focuses on advancing and commercializing medical dermatology products. The company's lead product candidate is PEP005, a patient-applied topical gel derived from the plant Euphorbia peplus, designed to treat actinic keratosis. PEP005 is currently in Phase III clinical trials. In addition to this, Peplin is also developing a physician-applied formulation of PEP005 for the treatment of superficial basal cell carcinoma. The active compound in both formulations is a small molecule extracted and purified from the sap of Euphorbia peplus. Peplin further expanded its capabilities in the dermatology sector by acquiring Neosil, Inc. in 2008, and was subsequently acquired by LEO Pharma A/S.